Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 21c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.43), $0.21 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $173.91 million versus the consensus estimate of $167.33 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Stagwell expands multi-year partnership with Adobe for enterprise marketing
• Popular stocks with increasing option volume: MSTR PLTR PCG SPCX MU INTC CRM SOFI PBR CRWD AMD MRVL